Sunshine Biopharma, Inc. (NASDAQ:SBFM) · earnings preview
Quarter
Q2
EPS estimate to actual
-$1.20
Revenue estimate to actual
$8.6M
At a glance
Key takeaways
01Sunshine Biopharma (SBFM) will report Q2 2026 earnings on August 11, 2026 after market close, with analysts expecting a loss of $1.20 per share compared to breakeven in the prior year quarter.
02Revenue is projected at $8.6 million, representing year-over-year growth, though the company trades at $1.22 per share with a market capitalization of $7.2 million.
03The company has a history of missing earnings estimates significantly, with Q1 2026 missing by 56.2% and Q4 2025 missing by 70.4%, both reporting larger losses than expected.
Earnings Results
Sunshine Biopharma, Inc. (NASDAQ:SBFM) is scheduled to report its Q2 earnings results on August 11, 2026 after market close.
Analysts expect the Healthcare company to report earnings per share of $-1.20, below the $0.00 reported in the same quarter last year. Revenue is expected to come in at $8.6M, up from a year ago.
Company Overview
The stock currently trades at $1.22 with a market capitalization of $7.2M.
Ahead of Sunshine Biopharma, Inc.'s earnings report, investors are watching several key metrics beyond the headline EPS number. Revenue growth, margin trends, and forward guidance will likely carry more weight than a single quarter's earnings figure in determining the stock's direction after the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Sunshine Biopharma, Inc. should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.